阴道近距离放疗可改善Ⅲ期子宫内膜癌宫颈受累患者的生存
基于美国国家癌症数据库2004—2013年Ⅲ期子宫内膜癌接受辅助盆腔外照射的患者,比较加用阴道近距离放疗(BT)与单纯外照射的生存差异。结果显示加用BT与5年生存改善相关(69%对66%,P<.01),多因素Cox风险比0.86(P<.01);获益主要见于宫颈内膜或宫颈间质受累者,倾向评分匹配后风险比0.80(P=.01)。
要点
- Ⅲ期子宫内膜癌辅助盆腔外照射加用阴道BT与生存改善相关。
- 生存获益集中于宫颈内膜或宫颈间质受累患者,无宫颈受累者未见获益。
- 切缘阳性或阴性、是否化疗均不影响BT的生存获益。
核心结论
- Ⅲ期子宫内膜癌辅助盆腔外照射加用阴道BT与生存改善相关。
- 获益主要见于宫颈内膜或宫颈间质受累患者,倾向评分匹配分析证实该获益。
研究设计与样本
- 回顾性队列研究,使用美国国家癌症数据库纳入2004—2013年Ⅲ期子宫内膜癌接受辅助盆腔外照射的患者。
- 共评估12988例患者,39%接受外照射加阴道BT;采用logistic回归、log-rank检验、Cox比例风险模型及倾向评分匹配分析。
主要发现
- 接受BT者更常见宫颈内膜或宫颈间质受累(比值比分别为2.03和1.77,P<.01)。
- 单纯外照射5年生存66%,加用BT为69%(P<.01)。
- 多因素Cox回归中BT仍显著预测死亡风险降低(风险比0.86,P<.01)。
- 无宫颈受累者加用BT未影响生存(P=.84);宫颈内膜或宫颈间质受累者加用BT显著改善生存(log-rank P<.01)。
- 倾向评分匹配分析中宫颈受累者加用BT风险比0.80(P=.01)。
关键数值与推荐
- Ⅲ期子宫内膜癌接受辅助盆腔外照射者,加用阴道BT的5年生存为69%,单纯外照射为66%(P<.01)。
- 多因素Cox回归中加用BT的风险比为0.86(P<.01)。
- 宫颈受累患者倾向评分匹配后加用BT的风险比为0.80(P=.01)。
临床怎么用
- 对Ⅲ期子宫内膜癌伴宫颈内膜或宫颈间质受累且接受辅助盆腔外照射者,可考虑加用阴道BT以改善生存。
- 无宫颈受累者加用BT未见生存获益,决策时应结合个体情况。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate the survival benefit of adding vaginal brachytherapy (BT) to pelvic external beam radiation therapy (EBRT) in women with stage III endometrial cancer. METHODS AND MATERIALS: The National Cancer Data Base was used to identify patients with stage III endometrial cancer from 2004 to 2013. Only women who received adjuvant EBRT were analyzed. Women were grouped according to receipt of BT. Logistic regression modeling was used to identify predictors of receiving BT. Log-rank statistics were used to compare survival outcomes. Cox proportional hazards modeling was used to evaluate the effect of BT on survival. A propensity score-matched analysis was also conducted among women with cervical involvement. RESULTS: We evaluated 12,988 patients with stage III endometrial carcinoma, 39% of whom received EBRT plus BT. Women who received BT were more likely to have endocervical or cervical stromal involvement (odds ratios 2.03 and 1.77; P<.01, respectively). For patients receiving EBRT alone, the 5-year survival was 66% versus 69% with the addition of BT at 5 years (P<.01). Brachytherapy remained significantly predictive of decreased risk of death (hazard ratio 0.86; P<.01) on multivariate Cox regression. The addition of BT to EBRT did not affect survival among women without cervical involvement (P=.84). For women with endocervical or cervical stromal invasion, the addition of BT significantly improved survival (log-rank P<.01). Receipt of EBRT plus BT was associated with improved survival in women with positive and negative surgical margins, and receiving chemotherapy did not alter the benefit of BT. Propensity score-matched analysis results confirmed the benefit of BT among women with cervical involvement (hazard ratio 0.80; P=.01). CONCLUSIONS: In this population of women with stage III endometrial cancer the addition of BT to EBRT was associated with an improvement in survival for women with endocervical or cervical stromal invasion.
引用
- Bingham B, Orton A, Boothe D, et al. Brachytherapy Improves Survival in Stage III Endometrial Cancer With Cervical Involvement. Int J Radiat Oncol Biol Phys. 2017. PMID: 28332987. doi:10.1016/j.ijrobp.2016.12.035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。